Search

Your search keyword '"Machet L"' showing total 899 results
Start Over Author "Machet L"
899 results on '"Machet L"'

6. Survie globale et prise en charge du syndrome de Sézary : étude rétrospective multicentrique de 402 cas

Author

Bozonnat, A., primary, Beylot-Barry, M., additional, Dereure, O., additional, D’Incan, M., additional, Quéreux, G., additional, Guenova, E., additional, Grange, F., additional, Viguier, M., additional, Ram-Wolff, C., additional, Boulinguez, S., additional, Troin, L., additional, Montaudié, H., additional, Feldmeyer, L., additional, Beltraminelli, H., additional, Bonnet, N., additional, Maubec, E., additional, Franck, N., additional, Machet, L., additional, Chasset, F., additional, Saiag, P., additional, Hainault, E., additional, Brunet Possenti, F., additional, Michel, C., additional, Bens, G., additional, Adamski, H., additional, Aubin, F., additional, Faiz, S., additional, Mortier, L., additional, Joly, P., additional, Tedbirt, B., additional, Templier, I., additional, Bouaziz, J.D., additional, Battistella, M., additional, Oro, S., additional, Bagot, M., additional, Serret-Larmande, A., additional, Montlahuc, C., additional, and de Masson, A., additional

Published
2022
Full Text
View/download PDF

8. Utilisation de la double immunothérapie par anti-CTLA-4 et anti-PD-1 chez les patients octogénaires et nonagénaires atteints de mélanome en France : premières données de l’étude rétrospective multicentrique IpiNivOver80

Author

Reichert, C., primary, Hachon, L., additional, Baldini, C., additional, Descamps, V., additional, Lebbé, C., additional, Allayous, C., additional, Delyon, J., additional, Maubec, E., additional, Bejar, C., additional, Baroudjian, B., additional, Faucon, C., additional, De Quatrebarbes, J., additional, Saiag, P., additional, Funck-Brentano, E., additional, Longvert, C., additional, Aubin, F., additional, Nardin, C., additional, Quéreux, G., additional, Khammari, A., additional, Beneton, N., additional, Adle, A., additional, Machet, L., additional, Mortier, L., additional, Zehou, O., additional, Jannic, A., additional, Malissen, N., additional, Richard, M.A., additional, and Brunet Possenti, F., additional

Published
2022
Full Text
View/download PDF

9. Efficacité et tolérance à long terme des schémas thérapeutiques testés chez les patients atteints de pemphigus inclus dans l’essai clinique Ritux 3

Author

Tedbirt, B., primary, Maho-Vaillant, M., additional, Houivet, E., additional, Calbo, S., additional, Prost-Squarcioni, C., additional, Labeille, B., additional, Picard-Dahan, C., additional, Konstantinou, M.P., additional, Chaby, G., additional, Richard, M.A., additional, Bouaziz, J.D., additional, Duvert Lehembre, S., additional, Delaporte, E., additional, Bernard, P., additional, Caux, F., additional, Alexandre, M., additional, Oro, S., additional, Vabres, P., additional, Quéreux, G., additional, Dupuy, A., additional, Debarbieux, S., additional, Avenel-Audran, M., additional, D’Incan, M., additional, Bedane, C., additional, Beneton, N., additional, Jullien, D., additional, Dupin, N., additional, Misery, L., additional, Machet, L., additional, Beylot-Barry, M., additional, Dereure, O., additional, Sassolas, B., additional, Benichou, J., additional, Joly, P., additional, and Hébert, V., additional

Published
2022
Full Text
View/download PDF

15. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study

Author

Jouary, T., Leyral, C., Dreno, B., Doussau, A., Sassolas, B., Beylot-Barry, M., Renaud-Vilmer, C., Guillot, B., Bernard, P., Lok, C., Bedane, C., Cambazard, F., Misery, L., Estève, E., Dalac, S., Machet, L., Grange, F., Young, P., Granel-Brocard, F., Truchetet, F., Vergier, B., Delaunay, M.M., and Grob, J.J.

Published
2012
Full Text
View/download PDF

21. 1080P HORIZON: Final results from a 5-year ambispective study of 705 patients who initiated pembrolizumab for advanced melanoma in the French early access program

Author

Grob, J.J., primary, Aubin, F., additional, Benmahammed-Bellagha, L., additional, Brunet-Possenti, F., additional, Dereure, O., additional, Dutriaux, C., additional, Duval-Modeste, A-B., additional, Grange, F., additional, Jarvis, C., additional, Kramkimel, N., additional, Leccia, M-T., additional, Machet, L., additional, Meyer, N., additional, Mortier, L., additional, Neidhardt, E-M., additional, Robert, C., additional, Scherrer, E., additional, Spampinato, A., additional, Verdoni, L., additional, and Saiag, P., additional

Published
2021
Full Text
View/download PDF

24. Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group

Author

Hurabielle, C., Ingen-Housz-Oro, S., Ortonne, N., Cornillet-Lefèbvre, P., Merah, A., DʼIncan, M., Joly, P., Franck, N., Estève, E., Maubec, E., Grange, F., Machet, L., Laroche, L., Barete, S., Dalac, S., Mortier, L., Michel, C., Quereux, G., Saiag, P., Ram-Wolff, C., Lenormand, B., Wechsler, J., Bastuji-Garin, S., Bagot, M., and Delfau-Larue, M. H.

Published
2015
Full Text
View/download PDF

26. Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial

Author

Bottomley, A., Coens, C., Mierzynska, J., Blank, C. U., Mandalà, M., Long, G. V., Atkinson, V. G., Dalle, S., Haydon, A. M., Meshcheryakov, A., Khattak, A., Carlino, M. S., Sandhu, S., Puig, S., Ascierto, P. A., Larkin, J., Lorigan, P. C., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A. M., van den Eertwegh, A. J. M., Grob, J. -J., Gutzmer, R., Jamal, R., van Akkooi, A. C. J., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S., Robert, C., Eggermont, A. M. M., EORTC Melanoma Group, Lesimple, T., Maio, M., Linette, G., Mortier, L., Svane, I. M., Schachter, J., Brown, M., Hersey, P., Barrow, C., Kudchadkar, R., Dutriaux, C., Song, X., Quaglino, P., Queirolo, P., Meier, F., Stroyakovskiy, D., Guillot, B., Romero, P. L. O., Bastholt, L., Garbe, C., Grange, F., Mohr, P., Algazi, A., Bechter, O., Hernberg, M., Loquai, C., Meiss, F., Chiarion Sileni, V., Bar-Sela, G., Fitzharris, B., Saiag, P., Arnault, J. -P., Simon, J. -C., Stephens, R., Baurain, J. -F., Lebbe, C., Combemale, P., Dummer, R., Hauschild, A., Parente, P., Yamazaki, N., Milhem, M., Leccia, M. -T., Geoffrois, L., Kretschmer, L., Dunwoodie, E., Walker, J., Lotem, M., Hendler, D., Mackiewicz, A., Sekulovic, L., Dzienis, M., Hospers, G. A. P., Siano, M., Hassel, J., Corrie, P., Passos, M. -J., Levin, M., Hoeller, C., Machet, L., Hallmeyer, S., Waterston, A., Descamps, V., Kiecker, F., Aarts, M., Schmidt, H., Raimundo, A., Nyakas, M., Lacour, J. -P., Berking, C., Ferrucci, P. F., Jameson, M., Kim, K., Yokota, K., Kerger, J., Aubin, F., Groenewegen, G., Kapiteijn, H., Boehncke, W. -H., Utikal, J., Casasola, R., Marshall, E., Ferraresi, V., Richtig, E., Matkovic, S., Inozume, T., Crook, T., Mcneil, C., Kiyohara, Y., Avril, M. -F., Hein, R., Terheyden, P., Nathan, P., Aoi, J., Skytta, T., Jouary, T., Takenouchi, T., Straume, O., Martins, C., Mukhametshina, G., Boehncke, Wolf-Henning, Internal medicine, CCA - Cancer Treatment and quality of life, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Ospedale 'Santa Maria della Misericordia' = University Hospital 'Santa Maria della Misericordia', The University of Sydney, Princess Alexandra Hospital, Brisbane, University of Queensland [Brisbane], Centre Léon Bérard [Lyon], Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Edith Cowan University (ECU), Universitat de Barcelona (UB), The Christie NHS Foundation Trust [Manchester, Royaume-Uni], Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology (MCMCC), Radboud University Medical Center [Nijmegen], Washington University School of Medicine in St. Louis, Washington University in Saint Louis (WUSTL), University Hospital of Siena, Amsterdam UMC - Amsterdam University Medical Center, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre de Recherche en Cancérologie de Marseille (CRCM), Aix Marseille Université (AMU)-Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Fédération nationale des Centres de lutte contre le Cancer (FNCLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hannover Medical School [Hannover] (MHH), Centre Hospitalier de l'Université de Montréal (CHUM), Université de Montréal (UdeM), Merck & Co. Inc, AP-HP. Université Paris Saclay, Institut Gustave Roussy (IGR), University Medical Center [Utrecht], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Montpellier (UM), Merck Sharp & Dohme., and Guided Treatment in Optimal Selected Cancer Patients (GUTS)

Subjects
Male, Skin Neoplasms, Medizin, Skin Neoplasms / drug therapy, Pembrolizumab, law.invention, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], MESH: Aged, 80 and over, 0302 clinical medicine, Melanoma / pathology, Randomized controlled trial, law, Monoclonal, 80 and over, Clinical endpoint, MESH: Double-Blind Method, 030212 general & internal medicine, Humanized, Melanoma, MESH: Aged, ddc:616, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Antibodies, Monoclonal, Humanized, Neoplasm Staging, Quality of Life, Double-Blind Method, Adult, Aged, Middle aged, Humans [MeSH], Hazard ratio, MESH: Neoplasm Staging, Middle Aged, Oncology, 030220 oncology & carcinogenesis, Female, Humans, medicine.medical_specialty, Melanoma / psychology, Skin Neoplasms / psychology, MESH: Melanoma, Antibodies, Monoclonal, Humanized / therapeutic use, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Antibodies, Melanoma / mortality, 03 medical and health sciences, Internal medicine, medicine, Adjuvant therapy, education, Skin Neoplasms / pathology, MESH: Humans, Melanoma / drug therapy, business.industry, MESH: Skin Neoplasms, MESH: Quality of Life, MESH: Adult, Skin Neoplasms / mortality, MESH: Male, Clinical trial, MESH: Antibodies, Monoclonal, Humanized, business, MESH: Female
Abstract

Background: The European Organisation for Research and Treatment of Cancer (EORTC) 1325-MG/KEYNOTE-054 trial in patients with resected, high-risk stage III melanoma demonstrated improved recurrence-free survival with adjuvant pembrolizumab compared with placebo (hazard ratio 0·57 [98·4% CI 0·43-0·74]; pMethods: This double-blind, randomised, controlled, phase 3 trial was done at 123 academic centres and community hospitals across 23 countries. Patients aged 18 years or older with previously untreated histologically confirmed stage IIIA, IIIB, or IIIC resected cutaneous melanoma, and an Eastern Cooperative Oncology Group performance status score of 1 or 0 were eligible. Patients were randomly assigned (1:1) using a central interactive voice-response system on the basis of a minimisation technique stratified for stage and geographic region to receive intravenously 200 mg pembrolizumab or placebo. Treatment was administered every 3 weeks for 1 year, or until disease recurrence, unacceptable toxicity, or death. The primary endpoint of the trial was recurrence-free survival (reported elsewhere). HRQOL was a prespecified exploratory endpoint, with global health/quality of life (GHQ) over 2 years measured by the EORTC QLQ-C30 as the primary analysis. Analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov, NCT02362594, and EudraCT, 2014-004944-37, and long-term follow-up is ongoing.Findings: Between Aug 26, 2015, and Nov 14, 2016, 1019 patients were assigned to pembrolizumab (n=514) or placebo (n=505). Median follow-up was 15·1 months (IQR 12·8-16·9) at the time of this analysis. HRQOL compliance was greater than 90% at baseline, greater than 70% during the first year, and greater than 60% thereafter for both groups. Because of low absolute compliance numbers at later follow-up, the analysis was truncated to week 84. Baseline GHQ scores were similar between groups (77·55 [SD 18·20] in the pembrolizumab group and 76·54 [17·81] in the placebo group) and remained stable over time. The difference in average GHQ score between the two groups over the 2 years was -2·2 points (95% CI -4·3 to -0·2). The difference in average score during treatment was -1·1 points (95% CI -3·2 to 0·9) and the difference in average score after treatment was -2·2 points (-4·8 to 0·4). These differences are within the 5-point clinical relevance threshold for the QLQ-C30 and are therefore clinically non-significant.Interpretation: Pembrolizumab does not result in a clinically significant decrease in HRQOL compared with placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting. placebo when given as adjuvant therapy for patients with resected, high-risk stage III melanoma. These results support the use of adjuvant pembrolizumab in this setting.

Published
2021

40. Étude du taux d’anticorps anti-BPAG2, mesuré par technique ELISA, comme biomarqueur des complications gravidiques au cours de la pemphigoïde de la grossesse

Author

Flament, J., primary, Jouen, F., additional, Tancrède-Bohin, E., additional, Oro, S., additional, Picard-Dahan, C., additional, Konstantinou, M.P., additional, Dereure, O., additional, Seta, V., additional, Quereux, G., additional, Prost, C., additional, Bedane, C., additional, Debarbieux, S., additional, Bourgault-Villada, I., additional, Delaporte, E., additional, Lacour, J.-P., additional, Richard, M.-A., additional, Pham-Ledard, A., additional, D’Incan, M., additional, Abasq, C., additional, Duvert-Lehembre, S., additional, Lombart, F., additional, Dupuy, A., additional, Hainaut, E., additional, Dompmartin, A., additional, Leccia, M.-T., additional, Vabres, P., additional, Alcaraz, I., additional, Michel, C., additional, Lagrange, B., additional, Litrowski, N., additional, Estève, E., additional, Machet, L., additional, Martin, L., additional, Del Giudice, P., additional, Fenot, M., additional, Belmondo, T., additional, Morin, F., additional, Tressières, B., additional, Joly, P., additional, and Cordel, N., additional

Published
2020
Full Text
View/download PDF

41. Pemphigoïdes bulleuses associées aux anti-PD-1/PDL-1 : étude nationale de 85 cas

Author

Juzot, C., primary, Sibaud, V., additional, Amatore, F., additional, Mansard, S., additional, Seta, V., additional, Jeudy, G., additional, Pham-Ledard, A., additional, Benzaquen, M., additional, Dinulescu, M., additional, Le Corre, Y., additional, Lesage, C., additional, Viguier, M., additional, Baroudjian, B., additional, Clerc, C.-J., additional, Funck-Brentano, E., additional, Giacchero, D., additional, Mortier, L., additional, Peuvrel, L., additional, Machet, L., additional, Duvert-Lehembre, S., additional, Viarnaud, A., additional, Joachim, C., additional, Bara, C., additional, Baubion, E., additional, Bergeret, B., additional, Brunet-Possenti, F., additional, Debarbieux, S., additional, Hébert, V., additional, Konstantinou, M.-P., additional, Marzouki-Zerouali, A., additional, Moreau-Huguen, J., additional, Phan, C., additional, Templier, I., additional, Celerier, P., additional, Aubin, F., additional, Modiano, P., additional, Poinas, A., additional, Vibet, M.-A., additional, Dréno, B., additional, and Quéreux, G., additional

Published
2020
Full Text
View/download PDF

42. Fiche conseil pour améliorer l’adhésion à la détection précoce d’un mélanome chez les apparentés au premier degré d’un patient atteint de mélanome (FADEMELA) : essai interventionnel randomisé en cluster

Author

Marce, D., primary, Caille, A., additional, Bridou, M., additional, Quereux, G., additional, Dupuy, A., additional, Lesimple, T., additional, Le Corre, Y., additional, Wierzbicka-Hainaut, E., additional, Legoupil, D., additional, Celerier, P., additional, Maillard, H., additional, Le Vilain-Abraham, F., additional, and Machet, L., additional

Published
2020
Full Text
View/download PDF

43. L’efficacité de l’imiquimod dans la prise en charge du mélanome de Dubreuilh in situ (lentigo malin)

Author

Khammari, A., primary, Dinulescu, M., additional, Nguyen, J.-M., additional, Cassecuel, J., additional, Maillard, H., additional, Le Duff, F., additional, Machet, L., additional, Beylot-Barry, M., additional, Legoupil, D., additional, Wierzbicka-Hainaut, E., additional, Bedane, C., additional, Leccia, M.-T., additional, Debarbieux, S., additional, Meyer, N., additional, Monestier, S., additional, Bens, G., additional, Denis, M., additional, Vourch, M., additional, Bossard, C., additional, Vergier, B., additional, and Dréno, B., additional

Published
2020
Full Text
View/download PDF

44. Traitement des patients atteints d’un mélanome métastatique cérébral par ipilimumab à haute dose et radiochirurgie : résultats à 5 ans

Author

Macaire, C., primary, Jamme, P., additional, Henri, M., additional, Robert, C., additional, Lesimple, T., additional, Thomas, L., additional, Machet, L., additional, Philippe, S., additional, Lebbe, C., additional, Dutriaux, C., additional, Grob, J.-J., additional, Duhamel, A., additional, Labreuche, J., additional, Desmedt, E., additional, Templier, C., additional, Mirabel, X., additional, Reyns, N., additional, Le Rhun, E., additional, and Mortier, L., additional

Published
2020
Full Text
View/download PDF

46. Étude de phase II de l’administration de pembrolizumab (MK-3475) en monothérapie et en première ligne chez des patients présentant un carcinome épidermoïde cutané non opérable

Author

Maubec, E., primary, Boubaya, M., additional, Petrow, P., additional, Beylot-Barry, M., additional, Basset-Seguin, N., additional, Deschamps, L., additional, Grob, J.J., additional, Dréno, B., additional, Scheer-Senyarich, I., additional, Bloch-Queyrat, C., additional, Leccia, M.-T., additional, Stefan, A., additional, Saiag, P., additional, Grange, F., additional, Meyer, N., additional, de Quatrebarbes, J., additional, Dinulescu, M., additional, Legoupil, D., additional, Machet, L., additional, Dereure, O., additional, Zehou, O., additional, Montaudié, H., additional, Wierzbicka-Hainaut, E., additional, Le Corre, Y., additional, Mansard, S., additional, Guegan, S., additional, Arnault, J.-P., additional, Dalac, S., additional, Aubin, F., additional, Alloux, C., additional, Lopez, I., additional, Cherbal, S., additional, Tibi, A., additional, and Levy, V., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results